{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:16:10Z","timestamp":1791983770686,"version":"4.4.0"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001703","name":"\u00c9cole Polytechnique F\u00e9d\u00e9rale de Lausanne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondation Bru","award":["BRU_PARKINSON"],"award-info":[{"award-number":["BRU_PARKINSON"]}]},{"name":"Joint Program for Neurodegenerative Diseases (JPND) from the UK Medical Research Council"},{"DOI":"10.13039\/100013128","name":"Multiple System Atrophy Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013128","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018889","name":"the Multiple System Atrophy Coalition","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018889","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fund Sophia, managed by the King Baudouin Foundation"},{"name":"Karin & Sten Mortstedt CBD Solutions"},{"name":"Reta Lila Weston Institute for Neurological Studies and the Medical Research Council UK"},{"name":"National Institute for Health Research University College London Hospitals Biomedical Research Centre"},{"DOI":"10.13039\/501100001809","name":"NNSF","doi-asserted-by":"crossref","award":["NNSF-81430025"],"award-info":[{"award-number":["NNSF-81430025"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"NNSF","doi-asserted-by":"crossref","award":["NNSF-81430025"],"award-info":[{"award-number":["NNSF-81430025"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["aSynProtec, REfrAME"],"award-info":[{"award-number":["aSynProtec, REfrAME"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["aSynProtec, REfrAME"],"award-info":[{"award-number":["aSynProtec, REfrAME"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EU-ITN","award":["Syndegen"],"award-info":[{"award-number":["Syndegen"]}]},{"name":"EU-ITN","award":["Syndegen"],"award-info":[{"award-number":["Syndegen"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-025-01084-y","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T11:26:00Z","timestamp":1756207560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Differential role of C-terminal truncations on alpha-synuclein pathology and Lewy body formation"],"prefix":"10.1038","volume":"11","author":[{"given":"Anne-Laure","family":"Mahul-Mellier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melek Firat","family":"Altay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niran","family":"Maharjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Ait-Bouziad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anass","family":"Chiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somanath","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Limorenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yllza","family":"Jasiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siv","family":"Vingill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wade-Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Holton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Haikal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Hamelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Croisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Knott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Mairet-Coello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Weerens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Citron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal A.","family":"Lashuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"1084_CR1","first-page":"S53","volume":"7","author":"M Goedert","year":"2017","unstructured":"Goedert, M., Jakes, R. & Spillantini, M. G. The synucleinopathies: twenty years on. J. Parkinsons Dis. 7, S53\u2013S71 (2017).","journal-title":"J. Parkinsons Dis."},{"key":"1084_CR2","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","volume":"281","author":"JP Anderson","year":"2006","unstructured":"Anderson, J. P. et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739\u201329752 (2006).","journal-title":"J. Biol. Chem."},{"key":"1084_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncb748","volume":"4","author":"H Fujiwara","year":"2002","unstructured":"Fujiwara, H. et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160\u2013164 (2002).","journal-title":"Nat. Cell Biol."},{"key":"1084_CR4","first-page":"879","volume":"152","author":"M Baba","year":"1998","unstructured":"Baba, M. et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson\u2019s disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879\u2013884 (1998).","journal-title":"Am. J. Pathol."},{"key":"1084_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0014-5793(98)01146-6","volume":"436","author":"RA Crowther","year":"1998","unstructured":"Crowther, R. A., Jakes, R., Spillantini, M. G. & Goedert, M. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett. 436, 309\u2013312 (1998).","journal-title":"FEBS Lett."},{"key":"1084_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.1471-4159.2001.00021.x","volume":"76","author":"BC Campbell","year":"2001","unstructured":"Campbell, B. C. et al. The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson\u2019s disease. J. Neurochem. 76, 87\u201396 (2001).","journal-title":"J. Neurochem."},{"key":"1084_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00401-009-0523-2","volume":"117","author":"I Alafuzoff","year":"2009","unstructured":"Alafuzoff, I. et al. Staging\/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol. 117, 635\u2013652 (2009).","journal-title":"Acta Neuropathol."},{"key":"1084_CR8","doi-asserted-by":"publisher","first-page":"49071","DOI":"10.1074\/jbc.M208046200","volume":"277","author":"M Hasegawa","year":"2002","unstructured":"Hasegawa, M. et al. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J. Biol. Chem. 277, 49071\u201349076 (2002).","journal-title":"J. Biol. Chem."},{"key":"1084_CR9","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.290.5493.985","volume":"290","author":"BI Giasson","year":"2000","unstructured":"Giasson, B. I. et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985\u2013989 (2000).","journal-title":"Science"},{"key":"1084_CR10","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.1021\/ja5131726","volume":"137","author":"R Burai","year":"2015","unstructured":"Burai, R., Ait-Bouziad, N., Chiki, A. & Lashuel, H. A. Elucidating the role of site-specific nitration of alpha-synuclein in the pathogenesis of Parkinson\u2019s disease via protein semisynthesis and mutagenesis. J. Am. Chem. Soc. 137, 5041\u20135052 (2015).","journal-title":"J. Am. Chem. Soc."},{"key":"1084_CR11","doi-asserted-by":"publisher","first-page":"28243","DOI":"10.1074\/jbc.M112.383711","volume":"287","author":"B Fauvet","year":"2012","unstructured":"Fauvet, B. et al. Characterization of semisynthetic and naturally N\u03b1-acetylated \u03b1-synuclein in vitro and in intact cells: implications for aggregation and cellular properties of \u03b1-synuclein. J. Biol. Chem. 287, 28243\u201328262 (2012).","journal-title":"J. Biol. Chem."},{"key":"1084_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-2978-8_1","volume":"1345","author":"B Fauvet","year":"2016","unstructured":"Fauvet, B. & Lashuel, H. A. Semisynthesis and enzymatic preparation of post-translationally modified alpha-synuclein. Methods Mol. Biol. 1345, 3\u201320 (2016).","journal-title":"Methods Mol. Biol."},{"key":"1084_CR13","doi-asserted-by":"publisher","first-page":"17726","DOI":"10.1073\/pnas.1315654110","volume":"110","author":"M Haj-Yahya","year":"2013","unstructured":"Haj-Yahya, M. et al. Synthetic polyubiquitinated \u03b1-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology. Proc. Natl. Acad. Sci. USA 110, 17726\u201317731 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1084_CR14","doi-asserted-by":"publisher","first-page":"5196","DOI":"10.1021\/ja210866j","volume":"134","author":"M Hejjaoui","year":"2012","unstructured":"Hejjaoui, M. et al. Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: alpha-synuclein phosphorylation at tyrosine 125. J. Am. Chem. Soc. 134, 5196\u20135210 (2012).","journal-title":"J. Am. Chem. Soc."},{"key":"1084_CR15","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1073\/pnas.1808845116","volume":"116","author":"PM Levine","year":"2019","unstructured":"Levine, P. M. et al. \u03b1-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson\u2019s disease. Proc. Natl. Acad. Sci. USA 116, 1511\u20131519 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1084_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/jmcb\/mjr011","volume":"3","author":"Y Liu","year":"2011","unstructured":"Liu, Y., Qiang, M., Wei, Y. & He, R. A novel molecular mechanism for nitrated {alpha}-synuclein-induced cell death. J. Mol. Cell Biol. 3, 239\u2013249 (2011).","journal-title":"J. Mol. Cell Biol."},{"key":"1084_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1021\/cn200074d","volume":"2","author":"Y Lu","year":"2011","unstructured":"Lu, Y., Prudent, M., Fauvet, B., Lashuel, H. A. & Girault, H. H. Phosphorylation of alpha-synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of alpha-synuclein in the pathogenesis of Parkinson\u2019s Disease and related disorders. ACS Chem. Neurosci. 2, 667\u2013675 (2011).","journal-title":"ACS Chem. Neurosci."},{"key":"1084_CR18","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1074\/jbc.M115.705095","volume":"291","author":"F Samuel","year":"2016","unstructured":"Samuel, F. et al. Effects of serine 129 phosphorylation on alpha-synuclein aggregation, membrane association, and internalization. J. Biol. Chem. 291, 4374\u20134385 (2016).","journal-title":"J. Biol. Chem."},{"key":"1084_CR19","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1016\/j.jmb.2019.04.026","volume":"431","author":"A Sanyal","year":"2019","unstructured":"Sanyal, A. et al. Alpha-synuclein is a target of fic-mediated adenylylation\/AMPylation: possible implications for Parkinson\u2019s disease. J. Mol. Biol. 431, 2266\u20132282 (2019).","journal-title":"J. Mol. Biol."},{"key":"1084_CR20","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.1016\/j.bmc.2017.04.038","volume":"25","author":"PM Levine","year":"2017","unstructured":"Levine, P. M. et al. O-GlcNAc modification inhibits the calpain-mediated cleavage of alpha-synuclein. Bioorg. Med. Chem. 25, 4977\u20134982 (2017).","journal-title":"Bioorg. Med. Chem."},{"key":"1084_CR21","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.bbadis.2009.01.012","volume":"1792","author":"C Cook","year":"2009","unstructured":"Cook, C. & Petrucelli, L. A critical evaluation of the ubiquitin-proteasome system in Parkinson\u2019s disease. Biochim. Biophys. Acta 1792, 664\u2013675 (2009).","journal-title":"Biochim. Biophys. Acta"},{"key":"1084_CR22","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1073\/pnas.0406976102","volume":"102","author":"W Li","year":"2005","unstructured":"Li, W. et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson\u2019s disease-linked mutations. Proc. Natl. Acad. Sci. USA 102, 2162\u20132167 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1084_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.neuroscience.2011.10.042","volume":"200","author":"G Muntane","year":"2012","unstructured":"Muntane, G., Ferrer, I. & Martinez-Vicente, M. alpha-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience 200, 106\u2013119 (2012).","journal-title":"Neuroscience"},{"key":"1084_CR24","doi-asserted-by":"publisher","unstructured":"Killinger, B. A. et al. The vermiform appendix impacts the risk of developing Parkinson\u2019s disease. Sci. Transl. Med. 10, https:\/\/doi.org\/10.1126\/scitranslmed.aar5280 (2018).","DOI":"10.1126\/scitranslmed.aar5280"},{"key":"1084_CR25","doi-asserted-by":"publisher","first-page":"22670","DOI":"10.1074\/jbc.M501508200","volume":"280","author":"CW Liu","year":"2005","unstructured":"Liu, C. W. et al. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J. Biol. Chem. 280, 22670\u201322678 (2005).","journal-title":"J. Biol. Chem."},{"key":"1084_CR26","doi-asserted-by":"publisher","first-page":"16233","DOI":"10.1021\/bi048453u","volume":"43","author":"W Hoyer","year":"2004","unstructured":"Hoyer, W., Cherny, D., Subramaniam, V. & Jovin, T. M. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry 43, 16233\u201316242 (2004).","journal-title":"Biochemistry"},{"key":"1084_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jmb.2011.05.046","volume":"411","author":"K Levitan","year":"2011","unstructured":"Levitan, K. et al. Conserved C-terminal charge exerts a profound influence on the aggregation rate of alpha-synuclein. J. Mol. Biol. 411, 329\u2013333 (2011).","journal-title":"J. Mol. Biol."},{"key":"1084_CR28","doi-asserted-by":"publisher","first-page":"8530","DOI":"10.1021\/bi027363r","volume":"42","author":"IV Murray","year":"2003","unstructured":"Murray, I. V. et al. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42, 8530\u20138540 (2003).","journal-title":"Biochemistry"},{"key":"1084_CR29","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1016\/j.bbadis.2018.10.003","volume":"1864","author":"L Ma","year":"2018","unstructured":"Ma, L. et al. C-terminal truncation exacerbates the aggregation and cytotoxicity of alpha-synuclein: a vicious cycle in Parkinson\u2019s disease. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 3714\u20133725 (2018).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"1084_CR30","doi-asserted-by":"publisher","unstructured":"Sorrentino, Z. A. et al. Physiological carboxy-truncation of alpha-synuclein potentiates the prion-like formation of pathological inclusions. J. Biol. Chem. https:\/\/doi.org\/10.1074\/jbc.RA118.005603 (2018).","DOI":"10.1074\/jbc.RA118.005603"},{"key":"1084_CR31","doi-asserted-by":"publisher","first-page":"13910","DOI":"10.1074\/jbc.RA118.001862","volume":"293","author":"M Terada","year":"2018","unstructured":"Terada, M. et al. The effect of truncation on prion-like properties of alpha-synuclein. J. Biol. Chem. 293, 13910\u201313920 (2018).","journal-title":"J. Biol. Chem."},{"key":"1084_CR32","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.1039\/C8SC01109E","volume":"9","author":"IM van der Wateren","year":"2018","unstructured":"van der Wateren, I. M., Knowles, T. P. J., Buell, A. K., Dobson, C. M. & Galvagnion, C. C-terminal truncation of alpha-synuclein promotes amyloid fibril amplification at physiological pH. Chem. Sci. 9, 5506\u20135516 (2018).","journal-title":"Chem. Sci."},{"key":"1084_CR33","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1523\/JNEUROSCI.4965-05.2006","volume":"26","author":"GK Tofaris","year":"2006","unstructured":"Tofaris, G. K. et al. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J. Neurosci. 26, 3942\u20133950 (2006).","journal-title":"J. Neurosci."},{"key":"1084_CR34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1750-1326-4-34","volume":"4","author":"JP Daher","year":"2009","unstructured":"Daher, J. P. et al. Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. Mol. Neurodegener. 4, 34 (2009).","journal-title":"Mol. Neurodegener."},{"key":"1084_CR35","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ajpath.2012.11.018","volume":"182","author":"D Games","year":"2013","unstructured":"Games, D. et al. Axonopathy in an alpha-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated alpha-synuclein. Am. J. Pathol. 182, 940\u2013953 (2013).","journal-title":"Am. J. Pathol."},{"key":"1084_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.expneurol.2014.11.003","volume":"264","author":"K Hall","year":"2015","unstructured":"Hall, K., Yang, S., Sauchanka, O., Spillantini, M. G. & Anichtchik, O. Behavioural deficits in transgenic mice expressing human truncated (1-120 amino acid) alpha-synuclein. Exp. Neurol. 264, 8\u201313 (2015).","journal-title":"Exp. Neurol."},{"key":"1084_CR37","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3727\/000000007783464911","volume":"16","author":"AW Michell","year":"2007","unstructured":"Michell, A. W. et al. The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson\u2019s disease. Cell Transpl. 16, 461\u2013474 (2007).","journal-title":"Cell Transpl."},{"key":"1084_CR38","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1460-9568.2010.07284.x","volume":"32","author":"A Ulusoy","year":"2010","unstructured":"Ulusoy, A., Febbraro, F., Jensen, P. H., Kirik, D. & Romero-Ramos, M. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur. J. Neurosci. 32, 409\u2013422 (2010).","journal-title":"Eur. J. Neurosci."},{"key":"1084_CR39","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.neurobiolaging.2006.11.017","volume":"29","author":"M Wakamatsu","year":"2008","unstructured":"Wakamatsu, M. et al. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Neurobiol. Aging 29, 574\u2013585 (2008).","journal-title":"Neurobiol. Aging"},{"key":"1084_CR40","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/j.1750-3639.2012.00597.x","volume":"22","author":"K Prasad","year":"2012","unstructured":"Prasad, K., Beach, T. G., Hedreen, J. & Richfield, E. K. Critical role of truncated alpha-synuclein and aggregates in Parkinson\u2019s disease and incidental Lewy body disease. Brain Pathol. 22, 811\u2013825 (2012).","journal-title":"Brain Pathol."},{"key":"1084_CR41","doi-asserted-by":"publisher","unstructured":"Moors, T. E. et al. The orchestration of subcellular alpha-synuclein pathology in the Parkinson\u2019s disease brain revealed by STED microscopy. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/470476 (2019).","DOI":"10.1101\/470476"},{"key":"1084_CR42","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.2353\/ajpath.2010.100552","volume":"177","author":"KA Lewis","year":"2010","unstructured":"Lewis, K. A. et al. Abnormal neurites containing C-terminally truncated alpha-synuclein are present in Alzheimer\u2019s disease without conventional Lewy body pathology. Am. J. Pathol. 177, 3037\u20133050 (2010).","journal-title":"Am. J. Pathol."},{"key":"1084_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104912","volume":"299","author":"S Quintin","year":"2023","unstructured":"Quintin, S. et al. Cellular processing of \u03b1-synuclein fibrils results in distinct physiological C-terminal truncations with a major cleavage site at residue Glu 114. J. Biol. Chem. 299, 104912 (2023).","journal-title":"J. Biol. Chem."},{"key":"1084_CR44","doi-asserted-by":"publisher","unstructured":"Lashuel, H. A. Do Lewy bodies contain alpha-synuclein fibrils? And does it matter? A brief history and critical analysis of recent reports. Neurobiol. Dis. 104876. https:\/\/doi.org\/10.1016\/j.nbd.2020.104876 (2020).","DOI":"10.1016\/j.nbd.2020.104876"},{"key":"1084_CR45","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00401-021-02329-9","volume":"142","author":"TE Moors","year":"2021","unstructured":"Moors, T. E. et al. The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson\u2019s disease brain as revealed by multicolor STED microscopy. Acta Neuropathol. 142, 423\u2013448 (2021).","journal-title":"Acta Neuropathol."},{"key":"1084_CR46","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","volume":"95","author":"MG Spillantini","year":"1998","unstructured":"Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469\u20136473 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1084_CR47","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s40478-021-01242-2","volume":"9","author":"EW Hass","year":"2021","unstructured":"Hass, E. W. et al. Disease-, region- and cell type specific diversity of \u03b1-synuclein carboxy terminal truncations in synucleinopathies. Acta Neuropathol. Commun. 9, 146 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"1084_CR48","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40478-022-01382-z","volume":"10","author":"TE Moors","year":"2022","unstructured":"Moors, T. E. et al. Multi-platform quantitation of alpha-synuclein human brain proteoforms suggests disease-specific biochemical profiles of synucleinopathies. Acta Neuropathol. Commun. 10, 82 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"1084_CR49","doi-asserted-by":"publisher","unstructured":"Poggiolini, I. et al. RT-QuIC using C-terminally truncated \u03b1-synuclein forms detects differences in seeding propensity of different brain regions from synucleinopathies. Biomolecules 11, https:\/\/doi.org\/10.3390\/biom11060820 (2021).","DOI":"10.3390\/biom11060820"},{"key":"1084_CR50","doi-asserted-by":"publisher","unstructured":"Altay, M. F. et al. Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2022.05.26.493598 (2023).","DOI":"10.1101\/2022.05.26.493598"},{"key":"1084_CR51","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s40478-022-01468-8","volume":"10","author":"MF Altay","year":"2022","unstructured":"Altay, M. F., Liu, A. K. L., Holton, J. L., Parkkinen, L. & Lashuel, H. A. Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders. Acta Neuropathol. Commun. 10, 163 (2022).","journal-title":"Acta Neuropathol. Commun."},{"key":"1084_CR52","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.2353\/ajpath.2007.061232","volume":"170","author":"BM Dufty","year":"2007","unstructured":"Dufty, B. M. et al. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol. 170, 1725\u20131738 (2007).","journal-title":"Am. J. Pathol."},{"key":"1084_CR53","doi-asserted-by":"publisher","first-page":"20051","DOI":"10.1073\/pnas.0908005106","volume":"106","author":"KC Luk","year":"2009","unstructured":"Luk, K. C. et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. USA 106, 20051\u201320056 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1084_CR54","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","volume":"72","author":"LA Volpicelli-Daley","year":"2011","unstructured":"Volpicelli-Daley, L. A. et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57\u201371 (2011).","journal-title":"Neuron"},{"key":"1084_CR55","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","volume":"338","author":"KC Luk","year":"2012","unstructured":"Luk, K. C. et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949\u2013953 (2012).","journal-title":"Science"},{"key":"1084_CR56","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bbagen.2015.10.007","volume":"1860","author":"L Pieri","year":"2016","unstructured":"Pieri, L. et al. Cellular response of human neuroblastoma cells to alpha-synuclein fibrils, the main constituent of Lewy bodies. Biochim. Biophys. Acta 1860, 8\u201319 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"1084_CR57","doi-asserted-by":"publisher","unstructured":"Mahul-Mellier, A.-L. et al. The making of a Lewy body: the role of \u03b1-synuclein post-fibrillization modifications in regulating the formation and the maturation of pathological inclusions. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/500058 (2018).","DOI":"10.1101\/500058"},{"key":"1084_CR58","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1073\/pnas.1913904117","volume":"117","author":"AL Mahul-Mellier","year":"2020","unstructured":"Mahul-Mellier, A. L. et al. The process of Lewy body formation, rather than simply \u03b1-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc. Natl. Acad. Sci. USA 117, 4971\u20134982 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1084_CR59","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/nprot.2014.143","volume":"9","author":"LA Volpicelli-Daley","year":"2014","unstructured":"Volpicelli-Daley, L. A., Luk, K. C. & Lee, V. M. Addition of exogenous alpha-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous alpha-synuclein to Lewy body and Lewy neurite-like aggregates. Nat. Protoc. 9, 2135\u20132146 (2014).","journal-title":"Nat. Protoc."},{"key":"1084_CR60","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/jnen\/62.12.1241","volume":"62","author":"E Kuusisto","year":"2003","unstructured":"Kuusisto, E., Parkkinen, L. & Alafuzoff, I. Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J. Neuropathol. Exp. Neurol. 62, 1241\u20131253 (2003).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1084_CR61","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/jnc.14569","volume":"149","author":"B Mollenhauer","year":"2019","unstructured":"Mollenhauer, B. et al. Antibody-based methods for the measurement of \u03b1-synuclein concentration in human cerebrospinal fluid\u2014method comparison and round robin study. J. Neurochem 149, 126\u2013138 (2019).","journal-title":"J. Neurochem"},{"key":"1084_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/srep05797","volume":"4","author":"JF Kellie","year":"2014","unstructured":"Kellie, J. F. et al. Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson\u2019s disease brain tissue by intact protein mass spectrometry. Sci. Rep. 4, 5797 (2014).","journal-title":"Sci. Rep."},{"key":"1084_CR63","doi-asserted-by":"publisher","first-page":"13482","DOI":"10.1074\/jbc.M117.780296","volume":"292","author":"RJ Karpowicz Jr","year":"2017","unstructured":"Karpowicz, R. J. Jr et al. Selective imaging of internalized proteopathic alpha-synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies. J. Biol. Chem. 292, 13482\u201313497 (2017).","journal-title":"J. Biol. Chem."},{"key":"1084_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111102","volume":"40","author":"A Bayati","year":"2022","unstructured":"Bayati, A. et al. Rapid macropinocytic transfer of \u03b1-synuclein to lysosomes. Cell Rep. 40, 111102 (2022).","journal-title":"Cell Rep."},{"key":"1084_CR65","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1016\/j.celrep.2016.08.053","volume":"16","author":"KC Luk","year":"2016","unstructured":"Luk, K. C. et al. Molecular and Biological Compatibility with Host Alpha-Synuclein Influences Fibril Pathogenicity. Cell Rep. 16, 3373\u20133387 (2016).","journal-title":"Cell Rep."},{"key":"1084_CR66","doi-asserted-by":"publisher","unstructured":"Kiely, A. P. et al. Exploring the putative role of kallikrein-6, calpain-1 and cathepsin-D in the proteolytic degradation of alpha-synuclein in multiple system atrophy. Neuropathol. Appl. Neurobiol. https:\/\/doi.org\/10.1111\/nan.12512 (2018).","DOI":"10.1111\/nan.12512"},{"key":"1084_CR67","doi-asserted-by":"publisher","first-page":"9322","DOI":"10.1073\/pnas.1500937112","volume":"112","author":"RP McGlinchey","year":"2015","unstructured":"McGlinchey, R. P. & Lee, J. C. Cysteine cathepsins are essential in lysosomal degradation of alpha-synuclein. Proc. Natl. Acad. Sci. USA 112, 9322\u20139327 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1084_CR68","doi-asserted-by":"publisher","first-page":"9678","DOI":"10.1021\/bi800699v","volume":"47","author":"D Sevlever","year":"2008","unstructured":"Sevlever, D., Jiang, P. & Yen, S. H. Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 47, 9678\u20139687 (2008).","journal-title":"Biochemistry"},{"key":"1084_CR69","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.nbd.2014.10.011","volume":"73","author":"A Tsujimura","year":"2015","unstructured":"Tsujimura, A. et al. Lysosomal enzyme cathepsin B enhances the aggregate forming activity of exogenous alpha-synuclein fibrils. Neurobiol. Dis. 73, 244\u2013253 (2015).","journal-title":"Neurobiol. Dis."},{"key":"1084_CR70","doi-asserted-by":"publisher","first-page":"9973","DOI":"10.1074\/jbc.RA119.008930","volume":"294","author":"RP McGlinchey","year":"2019","unstructured":"McGlinchey, R. P. et al. C-terminal alpha-synuclein truncations are linked to cysteine cathepsin activity in Parkinson\u2019s disease. J. Biol. Chem. 294, 9973\u20139984 (2019).","journal-title":"J. Biol. Chem."},{"key":"1084_CR71","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/nsmb.3433","volume":"24","author":"Z Zhang","year":"2017","unstructured":"Zhang, Z. et al. Asparagine endopeptidase cleaves alpha-synuclein and mediates pathologic activities in Parkinson\u2019s disease. Nat. Struct. Mol. Biol. 24, 632\u2013642 (2017).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1084_CR72","doi-asserted-by":"publisher","unstructured":"Karpowicz, R. J. Jr., Trojanowski, J. Q. & Lee, V. M. Transmission of alpha-synuclein seeds in neurodegenerative disease: recent developments. Lab. Investig. https:\/\/doi.org\/10.1038\/s41374-019-0195-z (2019).","DOI":"10.1038\/s41374-019-0195-z"},{"key":"1084_CR73","doi-asserted-by":"publisher","unstructured":"Mao, X. et al. Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353, https:\/\/doi.org\/10.1126\/science.aah3374 (2016).","DOI":"10.1126\/science.aah3374"},{"key":"1084_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08720-5","volume":"7","author":"E Ihse","year":"2017","unstructured":"Ihse, E. et al. Cellular internalization of alpha-synuclein aggregates by cell surface heparan sulfate depends on aggregate conformation and cell type. Sci. Rep. 7, 9008 (2017).","journal-title":"Sci. Rep."},{"key":"1084_CR75","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13024-022-00560-w","volume":"17","author":"K Chen","year":"2022","unstructured":"Chen, K. et al. LRP1 is a neuronal receptor for \u03b1-synuclein uptake and spread. Mol. Neurodegener. 17, 57 (2022).","journal-title":"Mol. Neurodegener."},{"key":"1084_CR76","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/bies.20759","volume":"30","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. & Yu, L. C. Single-cell microinjection technology in cell biology. Bioessays 30, 606\u2013610 (2008).","journal-title":"Bioessays"},{"key":"1084_CR77","doi-asserted-by":"publisher","unstructured":"Karim, M. R. et al. Internalized \u03b1-synuclein fibrils become truncated and resist degradation in neurons while glial cells rapidly degrade \u03b1-synuclein fibrils. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.06.05.597615 (2024).","DOI":"10.1101\/2024.06.05.597615"},{"key":"1084_CR78","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.stemcr.2017.06.005","volume":"9","author":"JE Beevers","year":"2017","unstructured":"Beevers, J. E. et al. MAPT genetic variation and neuronal maturity alter isoform expression affecting axonal transport in iPSC-derived dopamine neurons. Stem Cell Rep. 9, 587\u2013599 (2017).","journal-title":"Stem Cell Rep."},{"key":"1084_CR79","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature10648","volume":"480","author":"S Kriks","year":"2011","unstructured":"Kriks, S. et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson\u2019s disease. Nature 480, 547\u2013551 (2011).","journal-title":"Nature"},{"key":"1084_CR80","first-page":"552","volume":"26","author":"C Sandor","year":"2017","unstructured":"Sandor, C. et al. Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson\u2019s disease. Hum. Mol. Genet. 26, 552\u2013566 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"1084_CR81","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1523\/JNEUROSCI.1833-10.2011","volume":"31","author":"SZ Imam","year":"2011","unstructured":"Imam, S. Z. et al. Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson\u2019s disease. J. Neurosci. 31, 157\u2013163 (2011).","journal-title":"J. Neurosci."},{"key":"1084_CR82","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00401-013-1096-7","volume":"125","author":"AP Kiely","year":"2013","unstructured":"Kiely, A. P. et al. alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson\u2019s disease and multiple system atrophy?. Acta Neuropathol. 125, 753\u2013769 (2013).","journal-title":"Acta Neuropathol."},{"key":"1084_CR83","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/bpa.12845","volume":"30","author":"M Fayyad","year":"2020","unstructured":"Fayyad, M. et al. Investigating the presence of doubly phosphorylated \u03b1-synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases. Brain Pathol. 30, 831\u2013843 (2020).","journal-title":"Brain Pathol."},{"key":"1084_CR84","doi-asserted-by":"publisher","first-page":"7823","DOI":"10.1021\/ac901176t","volume":"81","author":"SR Danielson","year":"2009","unstructured":"Danielson, S. R. et al. Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson\u2019s disease. Anal. Chem. 81, 7823\u20137828 (2009).","journal-title":"Anal. Chem."},{"key":"1084_CR85","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1021\/acs.jproteome.8b00982","volume":"18","author":"P Bhattacharjee","year":"2019","unstructured":"Bhattacharjee, P. et al. Mass spectrometric analysis of lewy body-enriched \u03b1-synuclein in Parkinson\u2019s disease. J. Proteome Res. 18, 2109\u20132120 (2019).","journal-title":"J. Proteome Res."},{"key":"1084_CR86","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s11064-011-0527-x","volume":"36","author":"A Ohrfelt","year":"2011","unstructured":"Ohrfelt, A. et al. Identification of novel \u03b1-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method. Neurochem. Res. 36, 2029\u20132042 (2011).","journal-title":"Neurochem. Res."},{"key":"1084_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.101978","volume":"90","author":"SK Suthar","year":"2023","unstructured":"Suthar, S. K. & Lee, S. Y. Truncation or proteolysis of \u03b1-synuclein in Parkinsonism. Ageing Res. Rev. 90, 101978 (2023).","journal-title":"Ageing Res. Rev."},{"key":"1084_CR88","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1021\/acsanm.9b01331","volume":"3","author":"JW Smith","year":"2020","unstructured":"Smith, J. W. et al. Polymer-peptide conjugates convert amyloid into protein nanobundles through fragmentation and lateral association. ACS Appl. Nano Mater. 3, 937\u2013945 (2020).","journal-title":"ACS Appl. Nano Mater."},{"key":"1084_CR89","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.molcel.2015.07.012","volume":"59","author":"X Gao","year":"2015","unstructured":"Gao, X. et al. Human Hsp70 disaggregase reverses Parkinson\u2019s-linked alpha-synuclein amyloid fibrils. Mol. Cell 59, 781\u2013793 (2015).","journal-title":"Mol. Cell"},{"key":"1084_CR90","doi-asserted-by":"publisher","unstructured":"Tittelmeier, J. et al. The HSP110\/HSP70 disaggregation system generates spreading-competent toxic \u03b1-synuclein species. EMBO J. e103954. https:\/\/doi.org\/10.15252\/embj.2019103954 (2020).","DOI":"10.15252\/embj.2019103954"},{"key":"1084_CR91","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fnmol.2017.00098","volume":"10","author":"B Mannini","year":"2017","unstructured":"Mannini, B. & Chiti, F. Chaperones as suppressors of protein misfolded oligomer toxicity. Front. Mol. Neurosci. 10, 98 (2017).","journal-title":"Front. Mol. Neurosci."},{"key":"1084_CR92","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1093\/hmg\/ddu112","volume":"23","author":"M Diepenbroek","year":"2014","unstructured":"Diepenbroek, M. et al. Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-synuclein processing, aggregation and synaptic impairment in [A30P]alphaSyn transgenic mice. Hum. Mol. Genet. 23, 3975\u20133989 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"1084_CR93","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1046\/j.1471-4159.2003.01878.x","volume":"86","author":"AJ Mishizen-Eberz","year":"2003","unstructured":"Mishizen-Eberz, A. J. et al. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J. Neurochem. 86, 836\u2013847 (2003).","journal-title":"J. Neurochem."},{"key":"1084_CR94","doi-asserted-by":"publisher","first-page":"9593","DOI":"10.1073\/pnas.1609291113","volume":"113","author":"F Bassil","year":"2016","unstructured":"Bassil, F. et al. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc. Natl. Acad. Sci. USA 113, 9593\u20139598 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1084_CR95","doi-asserted-by":"publisher","first-page":"9958","DOI":"10.1073\/pnas.1610993113","volume":"113","author":"S Nuber","year":"2016","unstructured":"Nuber, S. & Selkoe, D. J. Caspase-1 clipping causes complications for alpha-synuclein. Proc. Natl. Acad. Sci. USA 113, 9958\u20139960 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1084_CR96","doi-asserted-by":"publisher","first-page":"9587","DOI":"10.1073\/pnas.1610099113","volume":"113","author":"W Wang","year":"2016","unstructured":"Wang, W. et al. Caspase-1 causes truncation and aggregation of the Parkinson\u2019s disease-associated protein alpha-synuclein. Proc. Natl. Acad. Sci. USA 113, 9587\u20139592 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1084_CR97","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/j.1460-9568.2007.05736.x","volume":"26","author":"M Takahashi","year":"2007","unstructured":"Takahashi, M. et al. Oxidative stress-induced phosphorylation, degradation and aggregation of alpha-synuclein are linked to upregulated CK2 and cathepsin D. Eur. J. Neurosci. 26, 863\u2013874 (2007).","journal-title":"Eur. J. Neurosci."},{"key":"1084_CR98","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neulet.2008.02.057","volume":"436","author":"T Kasai","year":"2008","unstructured":"Kasai, T. et al. Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro. Neurosci. Lett. 436, 52\u201356 (2008).","journal-title":"Neurosci. Lett."},{"key":"1084_CR99","doi-asserted-by":"publisher","first-page":"25216","DOI":"10.1074\/jbc.M503341200","volume":"280","author":"JY Sung","year":"2005","unstructured":"Sung, J. Y. et al. Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. J. Biol. Chem. 280, 25216\u201325224 (2005).","journal-title":"J. Biol. Chem."},{"key":"1084_CR100","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.expneurol.2008.10.010","volume":"215","author":"J Levin","year":"2009","unstructured":"Levin, J. et al. Increased alpha-synuclein aggregation following limited cleavage by certain matrix metalloproteinases. Exp. Neurol. 215, 201\u2013208 (2009).","journal-title":"Exp. Neurol."},{"key":"1084_CR101","doi-asserted-by":"publisher","first-page":"14168","DOI":"10.1074\/jbc.M111.222430","volume":"286","author":"DH Choi","year":"2011","unstructured":"Choi, D. H. et al. Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death. J. Biol. Chem. 286, 14168\u201314177 (2011).","journal-title":"J. Biol. Chem."},{"key":"1084_CR102","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/0306-4522(96)00100-5","volume":"73","author":"A Mouatt-Prigent","year":"1996","unstructured":"Mouatt-Prigent, A., Karlsson, J. O., Agid, Y. & Hirsch, E. C. Increased M-calpain expression in the mesencephalon of patients with Parkinson\u2019s disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death?. Neuroscience 73, 979\u2013987 (1996).","journal-title":"Neuroscience"},{"key":"1084_CR103","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1152\/physrev.1991.71.3.813","volume":"71","author":"DE Croall","year":"1991","unstructured":"Croall, D. E. & DeMartino, G. N. Calcium-activated neutral protease (calpain) system: structure, function, and regulation. Physiol. Rev. 71, 813\u2013847 (1991).","journal-title":"Physiol. Rev."},{"key":"1084_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15813-8","volume":"7","author":"M Karampetsou","year":"2017","unstructured":"Karampetsou, M. et al. Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice. Sci. Rep. 7, 16533 (2017).","journal-title":"Sci. Rep."},{"key":"1084_CR105","doi-asserted-by":"publisher","first-page":"15194","DOI":"10.1074\/jbc.M113.457408","volume":"288","author":"SA Tanik","year":"2013","unstructured":"Tanik, S. A., Schultheiss, C. E., Volpicelli-Daley, L. A., Brunden, K. R. & Lee, V. M. Lewy body-like alpha-synuclein aggregates resist degradation and impair macroautophagy. J. Biol. Chem. 288, 15194\u201315210 (2013).","journal-title":"J. Biol. Chem."},{"key":"1084_CR106","doi-asserted-by":"publisher","first-page":"5870","DOI":"10.1523\/JNEUROSCI.2705-16.2017","volume":"37","author":"MX Henderson","year":"2017","unstructured":"Henderson, M. X. et al. Unbiased proteomics of early Lewy body formation model implicates active microtubule affinity-regulating kinases (MARKs) in synucleinopathies. J. Neurosci. 37, 5870\u20135884 (2017).","journal-title":"J. Neurosci."},{"key":"1084_CR107","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00401-008-0375-1","volume":"116","author":"EA Waxman","year":"2008","unstructured":"Waxman, E. A., Duda, J. E. & Giasson, B. I. Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol. 116, 37\u201346 (2008).","journal-title":"Acta Neuropathol."},{"key":"1084_CR108","doi-asserted-by":"publisher","unstructured":"Guerrero-Ferreira, R. et al. Cryo-EM structure of alpha-synuclein fibrils. eLife 7, https:\/\/doi.org\/10.7554\/eLife.36402 (2018).","DOI":"10.7554\/eLife.36402"},{"key":"1084_CR109","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41422-018-0075-x","volume":"28","author":"Y Li","year":"2018","unstructured":"Li, Y. et al. Amyloid fibril structure of \u03b1-synuclein determined by cryo-electron microscopy. Cell Res. 28, 897\u2013903 (2018).","journal-title":"Cell Res."},{"key":"1084_CR110","doi-asserted-by":"publisher","unstructured":"Donzelli, S. et al. Post-fibrillization nitration of alpha-synuclein abolishes its seeding activity and pathology formation in primary neurons and in vivo. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.03.24.534149 (2023).","DOI":"10.1101\/2023.03.24.534149"},{"key":"1084_CR111","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/1873-3468.13728","volume":"594","author":"ZA Sorrentino","year":"2020","unstructured":"Sorrentino, Z. A., Xia, Y., Gorion, K. M., Hass, E. & Giasson, B. I. Carboxy-terminal truncations of mouse \u03b1-synuclein alter aggregation and prion-like seeding. FEBS Lett. 594, 1271\u20131283 (2020).","journal-title":"FEBS Lett."},{"key":"1084_CR112","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s40478-019-0859-3","volume":"7","author":"NL Rey","year":"2019","unstructured":"Rey, N. L. et al. \u03b1-Synuclein conformational strains spread, seed and target neuronal cells differentially after injection into the olfactory bulb. Acta Neuropathol. Commun. 7, 221 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"1084_CR113","doi-asserted-by":"publisher","unstructured":"Sorrentino, Z. A. et al. Carboxy-terminal truncation and phosphorylation of \u03b1-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy. Neurosci. Lett. 135017. https:\/\/doi.org\/10.1016\/j.neulet.2020.135017 (2020).","DOI":"10.1016\/j.neulet.2020.135017"},{"key":"1084_CR114","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1084\/jem.20112457","volume":"209","author":"KC Luk","year":"2012","unstructured":"Luk, K. C. et al. Intracerebral inoculation of pathological \u03b1-synuclein initiates a rapidly progressive neurodegenerative \u03b1-synucleinopathy in mice. J. Exp. Med. 209, 975\u2013986 (2012).","journal-title":"J. Exp. Med."},{"key":"1084_CR115","doi-asserted-by":"publisher","first-page":"7818","DOI":"10.1021\/bi047846q","volume":"44","author":"AJ Mishizen-Eberz","year":"2005","unstructured":"Mishizen-Eberz, A. J. et al. Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry 44, 7818\u20137829 (2005).","journal-title":"Biochemistry"},{"key":"1084_CR116","doi-asserted-by":"publisher","first-page":"13322","DOI":"10.1021\/bi7014053","volume":"46","author":"Z Qin","year":"2007","unstructured":"Qin, Z., Hu, D., Han, S., Hong, D. P. & Fink, A. L. Role of different regions of alpha-synuclein in the assembly of fibrils. Biochemistry 46, 13322\u201313330 (2007).","journal-title":"Biochemistry"},{"key":"1084_CR117","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12035-012-8280-y","volume":"47","author":"K Wakabayashi","year":"2013","unstructured":"Wakabayashi, K. et al. The Lewy body in Parkinson\u2019s disease and related neurodegenerative disorders. Mol. Neurobiol. 47, 495\u2013508 (2013).","journal-title":"Mol. Neurobiol."},{"key":"1084_CR118","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0002-9440(10)65220-0","volume":"155","author":"JG Culvenor","year":"1999","unstructured":"Culvenor, J. G. et al. Non-Abeta component of Alzheimer\u2019s disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am. J. Pathol. 155, 1173\u20131181 (1999).","journal-title":"Am. J. Pathol."},{"key":"1084_CR119","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/brain\/awp282","volume":"133","author":"J Tong","year":"2010","unstructured":"Tong, J. et al. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson\u2019s disease and progressive supranuclear palsy: a comparative investigation. Brain 133, 172\u2013188 (2010).","journal-title":"Brain"},{"key":"1084_CR120","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1046\/j.1471-4159.1999.02093.x","volume":"73","author":"WP Gai","year":"1999","unstructured":"Gai, W. P., Power, J. H., Blumbergs, P. C., Culvenor, J. G. & Jensen, P. H. Alpha-synuclein immunoisolation of glial inclusions from multiple system atrophy brain tissue reveals multiprotein components. J. Neurochem. 73, 2093\u20132100 (1999).","journal-title":"J. Neurochem."},{"key":"1084_CR121","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/S0002-9440(10)65226-1","volume":"155","author":"DW Dickson","year":"1999","unstructured":"Dickson, D. W. et al. Widespread alterations of alpha-synuclein in multiple system atrophy. Am. J. Pathol. 155, 1241\u20131251 (1999).","journal-title":"Am. J. Pathol."},{"key":"1084_CR122","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40478-024-01805-z","volume":"12","author":"GM Lloyd","year":"2024","unstructured":"Lloyd, G. M. et al. A multiverse of \u03b1-synuclein: investigation of prion strain properties with carboxyl-terminal truncation specific antibodies in animal models. Acta Neuropathol. Commun. 12, 91 (2024).","journal-title":"Acta Neuropathol. Commun."},{"key":"1084_CR123","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano, G. et al. Trial of prasinezumab in early-stage Parkinson\u2019s disease. N. Engl. J. Med. 387, 421\u2013432 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1084_CR124","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41531-023-00604-y","volume":"9","author":"MF Altay","year":"2023","unstructured":"Altay, M. F. et al. Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases. npj Parkinsons Dis. 9, 161 (2023).","journal-title":"npj Parkinsons Dis."},{"key":"1084_CR125","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.tins.2024.05.005","volume":"47","author":"N Ramalingam","year":"2024","unstructured":"Ramalingam, N., Haass, C. & Dettmer, U. Physiological roles of \u03b1-synuclein serine-129 phosphorylation\u2014not an oxymoron. Trends Neurosci. 47, 480\u2013490 (2024).","journal-title":"Trends Neurosci."},{"key":"1084_CR126","doi-asserted-by":"publisher","unstructured":"Wiseman, J. A. et al. Aggregate-prone brain regions in Parkinson\u2019s disease are rich in unique N-terminus \u03b1-synuclein conformers with high proteolysis susceptibility. npj Parkinsons Dis. 10, https:\/\/doi.org\/10.1038\/s41531-023-00614-w (2024).","DOI":"10.1038\/s41531-023-00614-w"},{"key":"1084_CR127","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3233\/JPD-223285","volume":"12","author":"L Petricca","year":"2022","unstructured":"Petricca, L. et al. Comparative analysis of total alpha-synuclein (\u03b1SYN) immunoassays reveals that they do not capture the diversity of modified \u03b1SYN proteoforms. J. Parkinsons Dis. 12, 1449\u20131462 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"1084_CR128","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s40478-021-01288-2","volume":"9","author":"NP Marotta","year":"2021","unstructured":"Marotta, N. P. et al. Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro. Acta Neuropathol. Commun. 9, 188 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"1084_CR129","doi-asserted-by":"publisher","first-page":"15345","DOI":"10.1074\/jbc.M111.318949","volume":"287","author":"B Fauvet","year":"2012","unstructured":"Fauvet, B. et al. alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J. Biol. Chem. 287, 15345\u201315364 (2012).","journal-title":"J. Biol. Chem."},{"key":"1084_CR130","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1038\/cdd.2015.79","volume":"22","author":"AL Mahul-Mellier","year":"2015","unstructured":"Mahul-Mellier, A. L. et al. Fibril growth and seeding capacity play key roles in alpha-synuclein-mediated apoptotic cell death. Cell Death Differ. 22, 2107\u20132122 (2015).","journal-title":"Cell Death Differ."},{"key":"1084_CR131","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/j.stemcr.2017.05.017","volume":"8","author":"W Haenseler","year":"2017","unstructured":"Haenseler, W. et al. A highly efficient human pluripotent stem cell microglia model displays a neuronal-co-culture-specific expression profile and inflammatory response. Stem Cell Rep. 8, 1727\u20131742 (2017).","journal-title":"Stem Cell Rep."},{"key":"1084_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09362-3","volume":"7","author":"W Haenseler","year":"2017","unstructured":"Haenseler, W. et al. Excess alpha-synuclein compromises phagocytosis in iPSC-derived macrophages. Sci. Rep. 7, 9003 (2017).","journal-title":"Sci. Rep."},{"key":"1084_CR133","doi-asserted-by":"publisher","first-page":"e0139591","DOI":"10.1371\/journal.pone.0139591","volume":"10","author":"D Dorin-Semblat","year":"2015","unstructured":"Dorin-Semblat, D. et al. Malaria parasite-infected erythrocytes secrete PfCK1, the plasmodium homologue of the pleiotropic protein kinase casein kinase 1. PLoS ONE 10, e0139591 (2015).","journal-title":"PLoS ONE"},{"key":"1084_CR134","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1074\/mcp.M113.031591","volume":"13","author":"J Cox","year":"2014","unstructured":"Cox, J. et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteom. 13, 2513\u20132526 (2014).","journal-title":"Mol. Cell. Proteom."},{"key":"1084_CR135","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1021\/pr500202e","volume":"13","author":"V Dorfer","year":"2014","unstructured":"Dorfer, V. et al. MS Amanda, a universal identification algorithm optimized for high accuracy tandem mass spectra. J. Proteome Res. 13, 3679\u20133684 (2014).","journal-title":"J. Proteome Res."},{"key":"1084_CR136","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2002-3-7-research0034","volume":"3","author":"J Vandesompele","year":"2002","unstructured":"Vandesompele, J. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, RESEARCH0034 (2002).","journal-title":"Genome Biol."},{"key":"1084_CR137","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1074\/mcp.R113.032730","volume":"12","author":"AW Schmid","year":"2013","unstructured":"Schmid, A. W., Fauvet, B., Moniatte, M. & Lashuel, H. A. Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol. Cell. Proteom. 12, 3543\u20133558 (2013).","journal-title":"Mol. Cell. Proteom."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01084-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01084-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01084-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T18:34:15Z","timestamp":1757442855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01084-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":137,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1084"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01084-y","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.M.C., A.M., P.D., and M.C. are employees of UCB Pharma. H.A.L. is the co-founder and chief scientific officer of ND BioSciences, Epalinges, Switzerland, a company that develops diagnostics and treatments for neurodegenerative diseases (NDs) based on platforms that reproduce the complexity and diversity of proteins implicated in NDs and their pathologies. H.A.L. has received funding from industry to support research on neurodegenerative diseases, including Merck Serono, UCB, and AbbVie. These companies had no specific role in the conceptualization, preparation, and decision to publish this manuscript. H.A.L. is the associate editor of npj Parkinson\u2019s Disease. H.A.L. was not involved in the journal\u2019s review of, or decisions related to, this manuscript. All other authors declare no competing financial interests in association with this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"261"}}